Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-CHOP vs CHOP in Untreated PTCL-TFH
NCT05678933Phase 3Enrolling by invitation
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azacitidine and tucidinostat in Peripheral T-cell lymphoma with T follicular helper cell phenotype (PTCL-TFH) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-Free Survival at 1 year. Started Jan 2023; status: enrolling by invitation.
02
Drugs
azacitidinetucidinostat
03
Conditions
Peripheral T-cell lymphoma with T follicular helper cell phenotype (PTCL-TFH)
Beyond the preview
Go deeper on NCT05678933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05678933.